View source for IRIS/Oral RfDs

{{Variable|moderator=KristiinaS}}

==Question==

What are the Oral RfDs according to the IRIS database?

==Answer==

<t2b index = "Substance,CASNR,Critical Effect,Observation type" locations = "Unit,Oral RfD,Type of RfD,Point of Departure,Overall Confidence,IRIS identifier" unit = "mg /kg /day">
Acenaphthene|83-32-9| Hepatotoxicity|mg /kg-day|6 x10-2|NOAEL|175|Low|0442
Acenaphthylene|208-96-8|Not Assessed under the IRIS program||||||0443
Acephate|30560-19-1|Inhibition of brain ChE|mg /kg-day|4 x10-3|LEL|0.12|High|0354
Acetaldehyde|75-07-0|Not Assessed under the IRIS program||||||0290
Acetochlor|34256-82-1|Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males|mg /kg-day|2 x10-2|NOAEL|2 mg/kg-day|High|0521
Acetone|67-64-1|Nephropathy|mg /kg-day|0.9|NOAEL|900|Medium|0128
Acetonitrile|75-05-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0205
Acetophenone|98-86-2|General toxicity|mg /kg-day|1 x10-1|NOAEL|423|Low|0321
Acetyl chloride|75-36-5|Not Assessed under the IRIS program||||||0518
Acifluorfen, sodium|62476-59-9|Mortality and kidney lesions|mg /kg-day|1.3 x10-2|NOEL|1.25|Medium|0192
Acrolein|107-02-8|Decreased survival|mg /kg-day|5 x10-4|NOAEL|0.05|Medium/High|0364
Acrylamide|79-06-1|Degenerative nerve changes|mg /kg-day|0.002|HED (BMDL)|0.053|Medium/High|0286
Acrylic acid|79-10-7|Reduced pup weight|mg /kg-day|5 x10-1|NOAEL|53|High|0002
Acrylonitrile|107-13-1|Not Assessed under the IRIS program||||||0206
Adiponitrile|111-69-3|Not Assessed under the IRIS program||||||0515
Alachlor|15972-60-8|Hemosiderosis, hemolytic anemia|mg /kg-day|1 x10-2|NOAEL|1|High|0129
Alar|1596-84-5|No adverse effects|mg /kg-day|1.5 x10-1|NOEL|15|Low|0287
Aldicarb|116-06-3|Sweating as clinical sign of AChe inhibition (other effect: Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects Nausea, diarrhea, and other signs and symptoms)|mg /kg-day|1 x10-3|NOAEL|0.01|Medium|0003
Aldicarb sulfone|1646-88-4|Brain ChE inhibition in females|mg /kg-day|1 x10-3|NOAEL|0.11|Medium|0312
Aldrin|309-00-2|Liver toxicity|mg /kg-day|3 x10-5|LOAEL|0.025|Medium|0130
Ally|74223-64-6|Decreased body weight|mg /kg-day|2.5 x10-1|NOEL|25|High|0288
Allyl alcohol|107-18-6|Impaired renal function and increased liver and kidney weights|mg /kg-day|5 x10-3|NOEL|4.8|Low|0004
Allyl chloride|107-05-1|Not Assessed under the IRIS program||||||0387
Aluminum phosphide|20859-73-8|Body weight and clinical parameters|mg /kg-day|4 x10-4|NOAEL|0.043|Medium|0005
Amdro|67485-29-4|Increased organ weights|mg /kg-day|3 x10-4|NOEL|0.33|High|0207
Ametryn|834-12-8|Liver toxicity|mg /kg-day|9 x10-3|NOEL|8.6|Low|0208
4-Aminopyridine|504-24-5|Not Assessed under the IRIS program||||||0440
Amitraz|33089-61-1|Increased mean blood sugar concentration; slight hypothermia|mg /kg-day|2.5 x10-3|NOEL|0.25|Medium|0334
Ammonia|7664-41-7|Not Assessed under the IRIS program||||||0422
Ammonium acetate|631-61-8|Not Assessed under the IRIS program||||||0517
Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program||||||0516
Ammonium sulfamate|7773-06-0|Decrease in body weight|mg /kg-day|2 x10-1|NOEL|214.3|Low|0007
Aniline|62-53-3|Not Assessed under the IRIS program||||||0350
ortho-Anisidine|90-04-0|Not Assessed under the IRIS program||||||0610
Anthracene|120-12-7|No observed effects|mg /kg-day|3 x10-1|NOEL|1000|Low|0434
Antimony|7440-36-0|Longevity, blood glucose, and cholesterol|mg /kg-day|4 x10-4|LOAEL|0.35|Low|0006
Antimony trioxide|1309-64-4|Not Assessed under the IRIS program||||||0676
Apollo|74115-24-5|Liver effects; organ weight changes|mg /kg-day|1.3 x10-2|NOEL|1.25|High|0008
Aramite|140-57-8|Not Assessed under the IRIS program||||||0473
Aroclor 1016|12674-11-2|Reduced birth weights|mg /kg-day|7 x10-5|NOAEL|0.007|Medium|0462
Aroclor 1248|12672-29-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0649
Aroclor 1254|11097-69-1|Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes|mg /kg-day|2 x10-5|LOAEL|0.005|Medium|0389
Arsenic, inorganic|7440-38-2|Hyperpigmentation, keratosis and possible vascular complications|mg /kg-day|3 x10-4|NOAEL|0.0008|Medium|0278
Arsine|7784-42-1|Not Assessed under the IRIS program||||||0672
Asbestos|1332-21-4|Not Assessed under the IRIS program||||||0371
Assure|76578-14-8|Liver cell enlargement|mg /kg-day|9 x10-3|NOEL|0.9|High|0335
Asulam|3337-71-1|Lower ovarian weight, lower liver/body weight|mg /kg-day|5 x10-2|LEL|50|Medium|0284
Atrazine|1912-24-9|Decreased body weight gain (other effect: Cardiac toxicity and moderate-to-severe dilation of the right atrium)|mg /kg-day|3.5 x10-2|NOAEL|3.5|High|0209
Avermectin B1|65195-55-3|Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth|mg /kg-day|4 x10-4|NOEL|0.12|High|0381
Azobenzene|103-33-3|Not Assessed under the IRIS program||||||0351
Barium and Compounds|7440-39-3|Nephropathy|mg /kg-day|0.2|BMDL05|63|Medium|0010
Barium cyanide|542-62-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0009
Baygon|114-26-1|Mild cholinergic symptoms and RBD ChE inhibition|mg /kg-day|4 x10-3|LEL|0.36|Medium|0210
Bayleton|43121-43-3|Decreased body weight gain, erythrocyte count and hemoglobin level|mg /kg-day|3 x10-2|NOEL|2.5|High|0131
Baythroid|68359-37-5|Decreased body weights in males, inflammatory foci in kidneys of females|mg /kg-day|2.5 x10-2|NOEL|2.5|High|0132
Benefin|1861-40-1|Depressed erythrocyte counts|mg /kg-day|3 x10-1|NOAEL|25|Medium|0133
Benomyl|17804-35-2|Decreased pup weanling weights|mg /kg-day|5 x10-2|NOEL|5 mg/kg-day|High|0011
Bentazon (Basagran)|25057-89-0|Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs (other effect: Dose-related increase in red areas (presumed blood) in feces; coagulation defect)|mg /kg-day|3.0 x10-2|NOAEL (ADJ)|3.2|Medium|0134
Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program||||||0454
Benzaldehyde|100-52-7|Forestomach lesions, kidney toxicity|mg /kg-day|1 x10-1|NOEL|143|Low|0332
Benzene|71-43-2|Decreased lymphocyte count|mg /kg-day|4.0 x10-3|BMDL|1.2|Medium|0276
Benzidine|92-87-5|Brain cell vacuolization; liver cell alterations in females|mg /kg-day|3 x10-3|LOAEL|2.7|Medium|0135
</t2b>
<ref>http://en.opasnet.org/w/IRIS</ref>

==Rationale==

* [[IRIS]]

==See also==

* [[IRIS]]

==References==

<References/>

==Related files==

{{mfiles}}